Item 5.07. Submission of Matters to a Vote of Security Holders.
AbCellera Biologics Inc. (the "Company") held its Annual Meeting of Shareholders
(the "Annual Meeting") on June 15, 2021. As of April 19, 2021, the record date
for the Annual Meeting, there were 270,925,888 common shares of the Company
outstanding and entitled to vote at the Annual Meeting. The Company's
shareholders voted on the following matters, which are described in detail in
the Company's Definitive Proxy Statement filed with the U.S. Securities and
Exchange Commission on April 28, 2021: (i) to elect Véronique Lecault and John
Edward Hamer as Class I directors of the Company to serve for a three-year term
expiring at the Company's annual meeting of shareholders in 2024 and until his
or her successor has been elected and qualified ("Proposal 1"), and (ii) to
ratify the appointment of KPMG LLP as the Company's independent registered
public accounting firm for the fiscal year ending December 31, 2021 ("Proposal
2").
The Company's shareholders approved the election of Véronique Lecault and John
Edward Hamer as Class I directors recommended for election in Proposal 1 at the
Annual Meeting. The Company's shareholders voted for the Class I directors as
follows:
Nominee For Against Abstain
Véronique Lecault 157,974,274 10,311,986 1,087,724
John Edward Hamer 156,787,159 11,335,006 1,251,819
The broker non-votes for this Proposal 1 totaled 12,457,090 common shares.
The Company's shareholders approved Proposal 2. The votes cast at the Annual
Meeting were as follows:
For Against Abstain
181,726,536 62,376 42,162
No other matters were submitted to or voted on by the Company's shareholders at
the Annual Meeting.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses